Cytokinetics receives FDA approval for MYQORZO (aficamten) to treat symptomatic oHCM

CYTOKINETICS INC

FDA approved MYQORZO (aficamten) on Dec 19, 2025 for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
MYQORZO is an allosteric, reversible inhibitor of cardiac myosin motor activity, reducing contractility and LVOT obstruction.
Available in 5 mg, 10 mg, 15 mg, and 20 mg tablets.
Approval based on data showing improved functional capacity and symptoms in oHCM patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.